Rockwell Medical Regains Nasdaq Compliance After Reverse Split
RMTI sits 25% above its 52-week low of $4.885 on elevated volume (2.9× avg).
Summary
Rockwell Medical has regained compliance with Nasdaq's $1.00 minimum bid-price rule, closing a prior deficiency. The stock maintained a closing bid at or above $1.00 from July 1–15, 2026, following the 1-for-10 reverse split effective July 1. Nasdaq has now closed the matter, and the company is in full compliance with all continued listing requirements. This removes a key delisting risk that had been hanging over the stock. The reverse split was announced in late June and executed at the start of July, and this compliance notice confirms the intended outcome.
At the time of this announcement, RMTI was trading at $6.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.2M. The 52-week trading range was $4.89 to $21.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.